By Kim Polacek, APR, CPRC - June 04, 2021
If you want to know where the future of cancer care is heading, the American Society of Clinical Oncology (ASCO) Annual Meeting holds the answers. More than 40,000 experts from all areas of cancer come together for the meeting each spring to present new clinical trial data and innovations in cancer prevention, diagnosis and care. The multiday event is one of the largest scientific conferences in the world.
The theme of this year's meeting is “Equity: Every Patient. Every Day. Everywhere.” Presentations during the meeting will help highlight the importance of ensuring all patients have access to and benefit from the latest cancer advances and high-quality cancer care.
Moffitt Cancer Center’s team of world-renowned physicians and researchers work endlessly to carry out our mission to create a culture of diversity and inclusion for our patients, team members and the community as we strive to contribute to the prevention and cure of cancer.
Our scientists will once again be well represented at the ASCO Annual Meeting. Our faculty members are authors on nearly 100 of the 2,450 abstracts accepted for presentation during the four-day scientific program. Their studies cover many different cancer types and explore cutting edge advances in the areas of cellular immunotherapy, artificial intelligence, radiation therapy, triplet therapy and more. You can learn more about Moffitt’s scientific presentations at ASCO at www.Moffitt.org/ASCO and in the stories below.
Read Moffitt's ASCO 2021 Stories
New study results show cellular therapy could be an option for older patient population
More than 90% of women injected with the virus are alive up to three years later
Triplet therapy offers hope for stage 4 melanoma patients including those with brain metastases
New study results find the therapy is effective for certain lymphoma patients
Data presented at ASCO help researchers identify better treatment options for rare pelvic cancers
Initial findings from VANDAAM Study shows promise in predicting aggressive cancer in African American men